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Summary
Refractory status epilepticus (RSE) can be defined as status epilepticus that continues despite
treatment with benzodiazepines and one antiepileptic drug. RSE should be treated promptly to
prevent morbidity and mortality; however, scarce evidence is available to support the choice of
specific treatments. Major independent outcome predictors are age (not modifiable) and etiology
(that should be actively targeted). Recent recommendations for adults, relying upon limited
evidence, suggest that RSE treatment aggressiveness should be tailored to the clinical situation: to
minimize ICU-related complications, focal RSE without major consciousness impairment might
initially be approached more conservatively; conversely, early induction of pharmacological coma
is advisable in generalized-convulsive forms. At this stage, midazolam, propofol or barbiturates
represent the most used alternatives. Several other treatments, such as additional anesthetics, other
antiepileptic or immunomodulatory compounds, or non-pharmacological approaches
(electroconvulsive treatment, hypothermia), have been used in protracted RSE. Treatment lasting
weeks or months may sometimes result in a good outcome, as in selected cases after cerebral
anoxia and encephalitis. Well-designed prospective studies of this condition are urgently needed.
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Introduction
With an annual incidence of 10–40/100,000 1–3, status epilepticus (SE) is the second most
frequent neurological emergency (acute stroke being the first) with a risk of major morbidity
or mortality 4. Regardless of the time frame, SE persisting despite adequate administration
of benzodiazepines and at least one antiepileptic drug (AED) is labeled “refractory”
(RSE) 5, 6. This occurs in 23%–43% of patients with SE; not surprisingly the only
prospective study 6 estimates lower proportions than ICU-based retrospective
assessments 7–9. The occurrence of RSE has been mostly associated with acute, severe and
potentially fatal underlying etiologies, such as encephalitis, massive stroke, or rapidly
progressive primary brain tumors, and may be accompanied by severe impairment of
consciousness 6, 7, 10.
Over the last few decades, important advances in basic mechanisms underlying SE and RSE
have been achieved, mostly due to seminal animal studies. However, animal data cannot be
automatically translated to humans, and to date well-conducted studies on epidemiological,
clinical, and therapeutic aspects remain disappointingly, and somewhat surprisingly, scarce.
In fact, RSE treatment is not at all evidence-based, despite it being recognized as an
important entity in emergency and intensive care settings. The principal aim of this
overview is to summarize our current knowledge of RSE in adults, with particular attention
to the balance between risks and benefits of different treatment strategies, including rarely
used options. Given the substantial differences in pathophysiology and treatment approaches
in neonates and infants, our focus is on patients who are two years of age or older. We also
identify areas of interest for research, and highlight some major practical difficulties that
need to be addressed to design and conduct prospective, clinical studies on this topic.
Mortality and morbidity
The short-term fatality rates for RSE have been estimated between 16% and 39% 6–9; when
compared to non-refractory SE, mortality after RSE is about three times higher 6, 7. In fact,
for the majority of fatalities, death does not occur during persisting SE, but rather after its
(sometimes late) resolution, and is generally due to underlying clinical problems 6. This
illustrates the critical prognostic importance of SE etiology: together with age, etiology has
been consistently identified as the principal independent outcome predictor 6, 11–14. The
classical subdivision between acute-symptomatic vs. remote etiologies, with the former felt
to be more dangerous, only partly reflects the prognostic power. Indeed, AED withdrawal is
an acute etiology that is often related to good outcome, and primary brain tumors are remote
etiologies heralding bad prognosis. Recently, another etiological classification has been
suggested, in which “potentially fatal conditions” (implying that these may lead to death if
not specifically treated, such as large ischemic stroke or hemorrhage, central nervous
infection, severe systemic infection, malignant brain tumor, AIDS with CNS complications,
eclampsia, intracranial tumor, and others) have been shown to significantly better predict
outcome after SE 6,12. A longer duration of untreated SE may also render its control more
difficult 13; however, this does not seem to be a robust predictor 11, and applies mostly to
generalized-convulsive forms 12 during the first few hours 15.
The risk of epilepsy following an incident symptomatic SE event, especially if refractory 7,
is three times higher than after a first symptomatic seizure 16. The risk of cognitive sequelae
appears to depend on the underlying etiology: patients diagnosed with epilepsy, in whom SE
is usually due to AED withdrawal or spontaneous fluctuations of the epileptic threshold
(etiologies that rarely trigger RSE), do not seem to aggravate their neuropsychological
performances after a SE episode 17. “Functional outcome” appears poorer after RSE 6,
especially generalized-convulsive, 18. The likelihood of returning to baseline clinical
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conditions after RSE is as low as 21%, as opposed to 63% for non-refractory SE. Also the
need for admission to acute rehabilitation facilities for surviving patients doubles after RSE
(82% vs. 35%) 6.
Rationale for early treatment
Given the danger of RSE and the effects of duration on outcome, there is broad consensus
on the need for timely and effective pharmacologic treatment 5, 19–22. In addition, data from
the Veteran Affairs Cooperative Study showed that SE treatment becomes less effective as
the episode becomes more prolonged: “subtle”, or nonconvulsive SE with coma (a form
usually reflecting a longer duration) was controlled by the first medication in 15% of cases
compared to 55% in “overt” convulsive SE 23. Furthermore, a second or third agent was
effective in less than 10% of cases in either condition 24.
Generalized convulsive SE can cause many systemic complications, including cardiac
arrhythmias, temperature disturbances, electrolyte and glucose imbalance, rhabdomyolysis,
and pulmonary edema 25, 26. However, apart from rhabdomyolysis, these consequences are
also observed in experimental models after inhibition of muscular convulsions 27.
Mechanisms related to refractoriness to treatment have been elucidated in the last few
decades. Self-sustained SE in rats, induced by repetitive electrical stimulation of limbic
structures, responds to benzodiazepines (a GABAA receptor agonist) or phenytoin (a
sodium-channel blocker) only if these are administered early (i.e., within the first few
minutes). With time, SE becomes progressively resistant to those agents, while antagonists
of the N-methyl-D-aspartate (NMDA) receptor, mediating glutamate excitatory inputs,
become particularly efficacious in the late phase 28, 29. This switch of sensitivity to different
pharmacological compounds reflects loss of inhibition in ongoing SE 30, and indeed in vitro
models show that GABAA receptors are internalized into the neuronal cytoplasm 31. From
these observations, it appears that the window for successful pharmacologic intervention
using antiepileptic compounds, including benzodiazepines, is relatively limited. On the other
hand, there is still no clinical evidence that refractoriness is exclusively accounted for by
loss of inhibition. The various etiologies and biological backgrounds encountered in patients
suffering from SE are distinct from the controlled and relatively uniform conditions of
experiments on rodents, and represent an important limitation to the translation of those
findings to humans.
Basic principles of SE treatment
The principal aims in treating a patient in SE are to achieve rapid control of seizures and
avoid complications. During early stages it is essential to rule out imitators, since the correct
diagnosis may be impossible to detect once a patient has been placed under pharmacological
coma, potentially leading to dangerous iatrogenic complications. Acute movement disorders,
such as focal or segmental dystonias, tremors, and choreatic movements 32 may sometimes
present unilaterally in confused patients. At times, clonus in the context of spasticity, which
disappears after a passive movement, or shivering in a sedated patient, characterized by
high-frequency, rhythmic, proximally located movements, may be mistaken for SE. One
particularly challenging group is psychogenic non-epileptic seizures (PNES). As opposed to
seizures, these episodes are suggestion-prone, generally not stereotyped, and may occur with
or without subjective consciousness impairment. During the ictus, the eyes are often closed,
ventilatory drive is maintained, and the episode may present as uncoordinated,
discontinuous, and fluctuating in intensity 33. Importantly, physical injuries may be observed
in patients having PNES 34. A considerable proportion of PNES patients show prolonged
seizures that may be misdiagnosed as SE (making up to 50% of patients treated for RSE in a
retrospective study), leading to intensive care admissions with considerable risks of
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overtreatment 34–36. Laboratory studies can be helpful in this setting: PNES patients do not
have elevated serum lactate, prolactin, or creatine kinase.
The first steps of SE treatment run in parallel with diagnostic procedures. After attending to
pulmonary and cardiac function, control of seizures is the top priority and generally follows
the intravenous administration of a sequence of three groups of drugs 4, 37, 38 (Figure 1): 1)
benzodiazepines aimed at rapid SE control; 2) classical antiepileptic drugs (AED) targeted at
early resistant forms and longer-term coverage; and 3) general anesthetics for RSE.
Benzodiazepines represent currently the only evidence-based treatment, as shown in three
trials and a Cochrane review 23, 39–41. However, only one trial compared them to other
medications: lorazepam resulted statistically better than phenytoin (but not phenobarbital or
diazepam combined with phenytoin) 23. Use of an accepted and available protocol greatly
facilitates a smooth interplay between the different care providers (paramedics, neurologists,
emergency or ICU team) and probably contributes to a better prognosis 42.
The overall aggressiveness of treatment depends on the type of SE. Generalized convulsive
SE should be treated aggressively given the danger of systemic and neurological injury with
ongoing seizures 5, 43. Conversely, non-convulsive SE without marked impairment of
consciousness can usually be treated more conservatively, since its underlying
pathophysiology is not associated with the same degree of injury as that of generalized
convulsive SE. For example, in patients with idiopathic generalized epilepsy, epileptologists
typically treat SE episodes (absence or myoclonic SE) with benzodiazepines and VPA, and
do not rely on ICU admissions 44. The precise criteria for turning to induction of coma for
the treatment of complex-focal SE is debated 45–49, given that the treatment may lead to
various complications, such as infections (most patients with mechanical ventilation have
pneumonia), metabolic disturbances including medication side effects, ileus, neuropathy,
myopathy, thrombosis and embolic events, to cite only the most frequent 50. It is therefore
necessary to balance these risks with the benefit of rapid seizure control. A recently
developed and validated clinical SE severity score (STESS) may help to orient early
treatment strategy 51, 52. Including four variables (age, seizure semiology, extent of
consciousness impairment, and history of previous seizures, as etiology surrogate), the
STESS is readily applicable in emergency settings, relies on straightforward clinical criteria,
and has a robust negative predictive value for mortality (i.e., patients with a low score are
extremely unlikely to have a fatal outcome). It thus appears reasonable to proceed straight to
3rd-line treatment if the 2nd-line treatment (which takes at least 20–30 min to be effective)
has failed in patients with generalize-convulsive SE 4, 53. Conversely, at least in some
patients, partial RSE without major impairment of consciousness (and therefore a low
STESS) may initially be managed without anesthetic compounds for the first 24–36 hours 6;
this approach is also reflected in recent recommendations 5, 22, 37, 38, 54, 55.
Choices of anesthetic agents
When elective coma induction is warranted to control RSE, the initial choice is restricted to
three groups of compounds 56 (Table 1), whose common characteristic is the modulation of
GABAA receptors, although each acts on specific sites. Midazolam is a benzodiazepine that
is already being used as a 1st line treatment. Its half-life, short after single bolus, increases to
6–50 hours after prolonged administration. However, tachyphylaxis often develops within
24–48 hrs 57, requiring the perfusion dose to be constantly increased to maintain a constant
pharmacological action. Midazolam is therefore mostly used initially, or in combination
with propofol. No particular problems inherent to its pharmacodynamic or pharmacokinetic
properties have been described, and availability of an antidote (flumacenil) represents a
theoretical advantage over the other two groups.
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Propofol displays a short half-life, allowing rapid titration and withdrawal. Besides
modulating GABAA receptors, it acts on sodium and calcium channels, and possibly on
NMDA receptors 58. Due to its administration as an oil emulsion, it may induce the so-
called “propofol infusion syndrome” (PRIS), a syndrome of potentially fatal cardio-
circulatory collapse with lactic acidosis, hypertriglyceridaemia and rhabdomyolysis. PRIS is
due to impairment of mitochondrial activity and free fatty acid utilization, with resulting
mismatch between energy needs and utilization; catecholamines and glucocorticoids may
represent facilitating factors 59. Mainly described in young children (thus representing a
relative contraindication in this age group) and patients with brain trauma, PRIS has also
been reported in patients treated for RSE 60. A recent retrospective series estimated the
incidence of PRIS in RSE as 7% (fatal) and 38% (non-fatal) 61. However, these proportions
are in sharp contrast with other retrospective 62 and prospective studies 63, 64 reporting
incidences of 0%–7%, and may represent a selection bias. Nevertheless, prolonged
perfusions (more than 48 hours over 5 mg/kg/h) should be avoided, and repetitive checks of
serum lactate are mandatory for an early detection of this complication 59. Concomitant
benzodiazepines could lower the needed propofol dose 62, possibly reducing the PRIS risk.
The anesthetic barbiturate thiopental, or its metabolite pentobarbital, represents the oldest
compounds used in this setting. In addition to GABAA modulation, barbiturates show an
NMDA-antagonist action in vitro, which might be of interest considering RSE
pathophysiology 65. They have a long half-life (up to 36 hours) after continuous
administration, owing to a considerable tendency to accumulate in adipose tissue. This may
become challenging especially in older patients with pre-existent cardiovascular problems.
A meta-analysis of the use of barbiturates, propofol, or midazolam in RSE completed a
decade ago, mostly based on retrospective and heterogeneous case series, did not reveal any
significant difference in short-term mortality, although some variations were noted in both
immediate efficacy (favoring barbiturates) and tolerability (favoring midazolam and
propofol) 66. Another single-center retrospective analysis failed to show any outcome
difference among different anesthetics, used alone or in combination 9. Recently, a
multicenter randomized, unblinded trial assessing propofol and barbiturates in RSE,
interrupted because of insufficient recruitment, found that patients receiving barbiturates had
a markedly longer need for mechanical ventilation, while long-term outcome and
complications were comparable 64. In spite of the increasing elimination half-life of
midazolam after prolonged infusion, this compound virtually never induces a complete
suppression of cerebral activity for several days, as do barbiturates. Thus, despite lack of
strong evidence (and also in view of the availability of a pharmacological antidote
flumacenil), midazolam seems to represent the safest compound in this setting, but often
needs to be combined with propofol to obtain seizure control. Propofol has the advantage of
a short half-life, which allows for a rapid clinical assessment upon weaning. However, the
risk of PRIS requires very careful metabolic monitoring, and the drug should not be used in
young children. Barbiturates should probably be reserved for RSE cases refractory to the
other anesthetics in view of its prolonged elimination.
EEG targets
An EEG should be used to monitor the effects of anesthetics when treating RSE. A
potentially interesting alternative may be the bispectral index (BIS) 67, an automated,
amplitude integrated measure of a two-channel EEG derivation (that includes a burst-
suppression ratio), frequently used by anesthesiologists in the operation room to monitor
anesthesia depth; this, however, should not routinely replace EEG with a comprehensive
scalp coverage if the latter is available, as the difference between pharmacological induced
burst-suppression and “seizure suppression” patterns may be difficult to assess. The optimal
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extent of EEG suppression (i.e., seizure suppression, burst-suppression pattern, flat
recording) has not been addressed in prospective studies, and retrospective observations do
not clearly favor any of these options 9, 68. The same uncertainty applies to the optimal
length and tapering of anesthetic treatment. In light of our current knowledge, an initial
course of midazolam anesthesia targeting EEG burst-suppression with an interburst interval
of about 10 sec. for 24 hours, followed by progressive tapering over 6–12 hours under EEG
control, seems to represent a reasonable option. Propofol and, subsequently, barbiturates
may be used thereafter. Since triphasic waves are often seen during the anesthetic tapering,
it is important not to “chase” every sharply contoured EEG transient, and rather concentrate
on definite seizure patterns 69, 70.
Other pharmacological approaches (summarized in Table 2)
Numerous anecdotal case reports and small series describe treatment options for RSE that
does not respond to the first intravenous anesthetic agents; due to the lack of comparative
data their absolute value is difficult to assess. Other anesthetics may be used sequentially in
patients suffering from very long-lasting RSE, in alternation or combination with
midazolam, propofol, or barbiturates. Inhalational anesthetics, which act, in part, on
GABAA receptors appear to be effective in aborting RSE, but the effects seem to be
transient, and their administration requires the use of appropriate gas recovery systems (not
typically found outside of the operating room). Two small case series describe the use of
isoflurane with an end-tidal concentration of 1.2% – 5% for up to 55 days. Several patients
required vasopressors, paralytic ileus occurred in some, and the high fatality rates (43%–
67%) reflect the difficult long-term control and the impact of the underlying disease 71, 72.
Furthermore, one recent report of isoflurane in RSE raised questions about CNS toxicity,
especially in thalamic and cerebellar regions 73. The intravenous anesthetic agent ketamine
has also been tried in RSE, given its properties as an NMDA receptor antagonist and
favorable hemodynamic profiles. There are only a few reports on the use of ketamine in this
setting, describing dosages up to 7.5 mg/kg/h for several days, and the outcomes have been
mixed 74–77. However, given that the indiscriminate blockade of both extrasynaptic and
intrasynaptic NMDA receptors may be the basis of ketamine’s neurotoxicity 78, it has thus
been suggested that ketamine should always be combined with GABAergic drugs 79, 80, also
because of a possible synergistic effect 81.
Several other non-sedating pharmacological approaches are available and may be used
intravenously or orally (through the nasogastric tube) as add-on compounds to optimize RSE
control. Topiramate 82, 83, pregabaline 84, levetiracetam 85, and lacosamide 86 (the latter two
are increasingly prescribed also as 2nd line), have different and potentially synergistic
pharmacodynamic actions. Lidocaine modulates sodium channels. Initial boluses up to 5
mg/kg and perfusions of up to 6 mg/kg/hr have been described 87, but serum levels above
5mg/l may induce seizures 88. Interestingly, it may even prove successful in phenytoin-
refractory patients. A retrospective survey on 37 children in RSE showed a response to
lidocaine in 36%, and no major adverse events; mortality was not reported 88. Verapamil
may inhibit multidrug transporters that can lower AED availability in the brain 89. Few case
reports on its use in humans are available, but it appears safe (with cardiac monitoring) up to
dosages of 360mg/day 90, 91. Magnesium, which is responsible for blockade of the NMDA
receptor, has been mentioned anecdotally in RSE, but with unconvincing results even at
serum levels of 14 mmol/l 92, 93, apart from a recent report on two patients with
mitochondrial encephalopathy 94. Of note, high doses may induce neuromuscular blockade
that may mask clinical seizures. The use of the ketogenic diet in RSE is relatively recent and
possibly promising both in children and adults 95–97. The diet can be administered through a
nasogastric tube and should induce ketonuria; this approach may display its effect within a
few days.
Rossetti and Lowenstein Page 6
Lancet Neurol. Author manuscript; available in PMC 2012 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Since ultra-refractory RSE seems to represent the consequence of immunological processes
in many instances 10, 98–100, immunomodulatory treatment is often prescribed in this
setting 43, 93. Steroids, ACTH, plasma exchanges, or intravenous immunoglobulins may be
used alone or in sequential combination after the formal exclusion of infectious etiologies.
Non-pharmacological approaches (summarized in Table 3)
Pharmacological treatment may be supported and potentiated by non-pharmacological
therapeutic strategies; however, the latter mostly represent ultima ratio approaches in cases
of extremely refractory SE. Similar to the preceding section, the marked variability among
the reports in terms of clinical setting (particularly, etiologies and concomitant therapies)
greatly limits the generalizability of these treatments.
Resective surgery may represent a valuable option in selected cases when a definite seizure
focus generating the RSE episode can be identified in a non-eloquent brain area, 101. Acute
vagal nerve stimulation (VNS) implantation has been suggested to be effective in a few
cases 102–104. While the stimulation was already initiated in the operation room, the intensity
was progressively titrated over a few days up to 1.25 mA (with various regimens for the
other stimulation parameters); transitory bradycardia/asystole may occur in this setting 102.
Low-frequency (0.5–1 Hz) transcranial magnetic stimulation (TMS) at 90%–100% of the
resting motor threshold, at times applied after a short “priming” high frequency stimulation
(up to 100 Hz), has been reported to be transiently successful in patients with simple-partial
SE 105, 106, although loss of efficacy after the initial stimulations suggests the need for a
repetitive use. Electroconvulsive treatment (ECT) has also been applied in cases of
extremely resistant RSE. Patients were mostly exposed to 1–4 daily sessions of induced
electrographic seizures over a few consecutive days, resulting in permanent RSE control in
some patients 107–109. The antiseizure mechanism of ECT is essentially unknown.
Brain hypothermia exerts beneficial effects on several pathophysiological axes implicated in
acute cerebral injuries. In animal studies of SE, hypothermia has been shown to reduce
seizure severity and epileptic discharges, brain edema, and apopotosis 110. However, clinical
observations in RSE are limited. Mild hypothermia (31°–36°C) together with midazolam,
ketamine, or thiopental for one to several days has been reported to control RSE, but
seizures may recur after rewarming 50, 111–113. While side-effects (including electrolyte
disturbances, coagulation dysfunction, infections, cardiac arrhythmia) are relatively
infrequent in patients treated with hypothermia after cardiac arrest 114, paralytic ileus may
represent a challenging complication in patients with SE, especially when barbiturates are
co-administered 50.
Recently, the beneficial effect of classical music has been reported on both electrographic
and clinical parameters in a few patients with RSE, evident within hours of exposure 115.
The mechanism of action is entirely unknown.
When to stop RSE treatment
Although long-lasting RSE generally heralds a poor prognosis, some exactions exists:
patients suffering from RSE from several days, weeks, or even months may at times recover
with a good functional outcome 15, 100, 116–118. Certainly in some patients, most often those
with an infectious or autoimmune etiology, the underlying disease process subsides after
some time, allowing awakening of the patient without repetitive seizures. It appears
therefore advisable not to stop supportive treatment, including repetitive courses of
anesthetics if needed, just because of protracted treatment duration, if neuroimaging remains
normal, apart from minor signs of global atrophy 118, and no underlying etiology heralding a
catastrophic prognosis is identified (e.g., rapidly progressive brain tumors, paraneoplastic
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limbic encephalitis with disseminated primary cancer, prion disease). This especially applies
to younger patients, who are usually able to tolerate the cardiovascular side effects of long-
term anesthesia.
RSE in the setting of cerebral anoxia represents a controversial issue. This entity does not
seem to imply an invariably poor outcome. Although recent observations confirm that SE
occurring during therapeutic hypothermia and sedation, mostly presenting as a “seizure-
suppression” EEG pattern, represents a situation of extreme brain damage and extremely
poor outcome 119, 120, it has been reported that SE arising after rewarming may be treated as
SE if the EEG background remains reactive and somatosensory evoked potentials and
brainstem reflexes are preserved 121. In these rare cases, survival with reasonable functional
outcome has been reported after administration of AEDs and at times a single-course of
anesthetics. Conversely, the outcome remains dismal despite every therapeutic attempt in
patients showing severe loss of CNS function and EEG non-reactivity122.
Areas needing research
In contrast to the steadily growing basic-science literature on SE that continues to shed
important lights on underlying mechanisms, it is very disappointing to have such little
evidence for current approaches to SE treatment, apart from the 1st line of
benzodiazepines 43. This is accounted for by the fact that clinical studies represent a
daunting task in this setting. There is an urgent need to fill this gap.
Translational strategies bridging animal to human studies, aiming at identifying potential
molecular targets for novel treatments, need to be developed, with subsequent proof-of-
concept clinical trials to evaluate the clinical efficacy of candidate targets. Given that SE
represents a very heterogenous entity, it is unlikely that a single approach identified from
animal models will prove decisive. As an example, ketamine unfortunately does not appear
to give reliably good results in humans, as opposed to those in animal models. It seems
reasonable to think that more than one animal model should be developed to address the
multitude of etiologies associated with SE.
Regarding the general approach to treating RSE, it is unclear if other factors beside age and
etiology represent independent outcome predictors. For example, pre-existent comorbidities
(modifiable) 123, race (not modifiable) 2, and hospital settings (modifiable) 124, 125 have
received scarce attention to date. Duration of SE, emphasized in some studies 13, 18, may
actually reflect an early selection of SE forms that are intrinsically difficult to treat, rather
than a modifiable risk factor. It is unclear to what extent the use of a given SE treatment
protocol allows a better prognosis, apart from a recent single study 42. Also, the optimum
sequence and timing of initial SE treatment is essentially unexplored. Apart from these
questions, in view of potentially relevant differences in both efficacy 126 and tolerability 64,
well-designed trials assessing medication at the 2nd and 3rd line levels are clearly needed, as
well as controlled assessments on depth and duration of EEG suppression. As described in
the recent report of an aborted trial investigating 3rd line treatment 64, these studies have
failed up to now mainly because of difficulties in obtaining sufficient funding and the need
for a very large number of clinical sites for enrollment. As an example, a 3-armed trial
investigating a 2nd-line AED would need approximately 1500 enrolled patients in order to
detect differences that are potentially clinically relevant. Since a high-volume tertiary center
treats an average of 50–70 adults for SE yearly, and at best one-fourth of them will prove
eligible for the study, 50 centers would need to recruit for a minimum of two years in order
to complete the trial.
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Conclusion
Refractory SE represents a heterogeneous entity which is regularly encountered in every
hospital setting. There is a strong consensus about the need for an early, effective treatment
to prevent morbidity and mortality. In the first hours, it seems reasonable to tune treatment
aggressiveness (pharmacological coma induction) according to the clinical subtypes: while
generalized-convulsive SE must be approached aggressively, partial SE and SE related to
idiopathic generalized epilepsy (absence and myoclonic forms) can be treated initially with
non-sedating agents. Facing long-lasting RSE, which is usually related to particular
etiologies, it is mandatory not to stop supportive treatment unless irreversible brain damage
is proven. Furthermore, SE etiology is a potentially modifiable outcome predictor that
should always be specifically addressed. Finally, multicentric well-designed drug trials are
needed in order to improve the current management of RSE.
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Figure 1.
Flow chart of status epilepticus treatment*. Increasing refractoriness is illustrated by the
background color intensity; the non-sedating agents are green, anesthetics in orange to red,
and other options in yellow or white. First-line treatment is light green, second-line darker
green, and third line light and darker orange. Other options are given in red, yellow and
blue.
*Great caution is required for valproate in children under 2 years (hepatic toxicity), and
propofol in young children (propofol infusion syndrome). In this setting, benzodiazepines,
phenytoin and barbiturates represent the most widely used options.
CLZ: clonazepam; ECT: electroconvulsive treatment; KD: ketogenic diet; LCM:
lacosamide; LEV: levetiracetam; LZP: lorazepam; MDZ: midazolam; PGB: pregabaline;
PHT: phenytoin; PRO: propofol; PTB: pentobarbital; rTMS: repetitive transcranial magnetic
stimulation; SE: status epilepticus; THP: thiopental; TPM: topiramate; VNS: vagus nerve
stimulation; VPA: valproate.
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Table 1
Anesthetic agents used in RSE 5, 53, 56
Loading dose Maintenance dose Remarks
Midazolam 0.2 mg/kg 0.2–0.6 mg/kg/h Increasing doses needed with time
Propofol 2 mg/kg 2–5 (−10) mg/kg/h Attention to “PRIS”, especially in young children; combine with BDZ
Barbiturates THP: 1–2 mg/kg
PTB: 5 mg/kg
THP: 1–5 mg/kg/h
PTB: 1–5 mg/kg/h
Loading with repetitive boluses
Long wash-out time
BDZ: benzodiazepines; PRIS: propofol infusion syndrome; PTB: pentobarbital; RSE: refractory status epilepticus; THP: thiopental.
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Table 2
Other pharmacological and nutritional treatments for RSE (see text for references)
Advantages Disadvantages/Remarks
Isoflurane72 Fast acting Possible neurotoxicity Needs close system
Ketamine74–77 Anti-NMDA Possible neurotoxicity, combine with BDZ
Lidocaine 76, 77 May rescue PHT- resistant RSE Cardiac monitoring needed; possible seizures induction
Verapamil 90, 91 Safe Not AED action, may optimize availability of AED in CSF
Magnesium94 May enhance NMDA blockade May induce neuromuscular blockade
Ketogenic diet95, 96 Safe Need experienced dietologist; check ketonuria
Immunological Treatments93 May act causally Formal exclusion of infection before treatment
AED: antiepileptic drug; BDZ: benzodiazepines; CSF: cerebrospinal fluid; RSE: refractory status epilepticus
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Table 3
Non-pharmacological options for RSE (see text for references)
Advantages Disadvantages/Remarks
Resective surgery 101 May act causally Not appropriate in multifocal SE; need of experienced
interdisciplinary team; surgical risks
Vagal nerve stimulation 102 Appropriate for long-term use Invasive procedure; cardiac arrhythmias rarely reported
Repetitive transcranial
magnetic stimulation106
Non-invasive procedure Possible seizure induction; need to sustained treatment
Electroconvulsive
treatment 108, 109
Non-invasive procedure Need of experienced interdisciplinary team; possible seizure
induction
Mild hypothermia 112 Acts on several pathophysiological
mechanisms
Mostly only transitory control; avoid barbiturates (ileus)
Classical music 115 Pleasant for nursing team No side effects; scarcely reported
RSE: refractory status epilepticus
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